HORIZON
ANALYTICAL LABORATORY

Certificate of Analysis

REPORT NO.	VERIFICATION CODE	REVISION	ISSUED
NOV-26-16	HRZ-89MW-E53D	2	13-NOV-2026

SCAN TO VERIFY

SAMPLE

NAD+

Label claim: 500 mg / vial

OVERALL RESULT

✓ **Conforms to specification**

CLIENT	MANUFACTURER (DECLARED)	BATCH / LOT	APPEARANCE
Orca Life Bio	Orca Life UK	OR-NAD500-261102	White lyophilized powder

TESTING ORDERED	SAMPLE RECEIVED	ANALYSIS CONDUCTED	UNITS TESTED · BLIND CODE
04 NOV 2026	04 NOV 2026	05 NOV 2026	1 vial

PURITY · HPLC-UV
99.74 %
Area % (HPLC-UV)

CONTENT · HPLC-UV
487 mg
97.4 % of label claim

IDENTITY · LC-MS
Confirmed
664.10 m/z [M+H]+

ENDOTOXINS · LAL
Not tested
—


Detailed results

N = VIALS TESTED · SD · RELATIVE SD

PARAMETER	METHOD	RESULT	N	SD	%RSD	SPECIFICATION	STATUS
Purity (area %)	HPLC-01	99.74 %	1	n/a	n/a	≥ 98.0 %	CONFORMS
Content	HPLC-01	487 mg (97.4 %)	1	n/a	n/a	90–110 % of LC	CONFORMS
Identity	LCMS-02	664.10 m/z [M+H]+	1	n/a	n/a	Matches theor. MW	CONFORMS
Largest impurity	HPLC-01	0.17 %	1	n/a	n/a	Report	

HPLC chromatogram

Vial 1 · 280 nm



Sample as received

Method

HPLC-01

Column	C18, 150 × 4.6 mm, 3.5 µm, 40 °C
Mobile phase · gradient	0.1 % TFA in H_2O / ACN, 10→100 % B
Detection	DAD, 280 nm
LOD / LOQ	0.02 % / 0.05 %
Calibration	

Traceability

CHAIN OF CUSTODY

Reference standard	—
Instrument	HPLC-DAD / LC-MS
Storage on receipt	+4 °C
Seals on receipt	
Comments	Rev. 2 supersedes Rev. 1 – editorial corrections only; analytical data unchanged.

Yagız Akbaş · 06 NOV 2026
Analysed by · date

Yagız Akbaş · 06 NOV 2026
Reviewed by · date

Prof. Dr. Gizem Dinler Doğanay
Laboratory Director · approved · date

Verify at horizon-biosolutions.com · Verification / signature reference HRZ-89MW-E53D

Results relate only to the items tested, as received. Reproduce only in full. Research use only; no medical or therapeutic claim is made or implied.

Address Reşitpaşa, Katar Cd. İTÜ Tasarım ve Prototip Merkezi No:2/41 Kapı No:10, Sarıyer / İstanbul · Contact gizem.doganay@horizon-biosolutions.com